Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla-Serum add new rung to relationship

This article was originally published in Scrip

Executive Summary

This could be read as growing pre-nuptial synergy between Cipla and the Serum Institute of India. Or maybe the duo's next step in their "relationship" is purely an extension of a previous alliance and one which will see Cipla step up its indirect interest in vaccines play to the Indian market.

You may also be interested in...



Serum Institute Awaiting Gavi Push For $2 Pneumococcal Vaccine

Serum Institute hopes to hear by May from Gavi on whether it will consider the firm's $2 per dose pneumococcal conjugate vaccine for immunization programs across developing countries. Its 10-valent vaccine, versus GSK’s 11-valent and Pfizer’s 13-valent vaccines, is 30% cheaper.

Cipla Sees Changed Profile; Wraps Up Europe Revamp

Cipla's management sees the firm's profile changing as it scales up its US business with new launches and a step-up in product filing intensity. The Indian company is also "largely done" with a restructuring in Europe that saw a significant cutback in personnel but is expected to make the European business profit-accretive.

Hope For Price Flexibility After India Pretomanid Go-Ahead

Mylan gets approval in India for pretomanid as part of a combination regimen with bedaquiline and linezolid, providing new hope to patients with drug-resistant tuberculosis. Volume changes may provide opportunities to tweak prices.

Topics

Related Companies

UsernamePublicRestriction

Register

LL043097

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel